Neurochemistry

Saniona to Present Preclinical Data on SAN711 at the 7th Congress of the European Academy of Neurology

Retrieved on: 
Tuesday, June 8, 2021
Branches of biology, Neurochemistry, Gába, Transmembrane receptors, GABAA receptor, GABA receptor, gamma-Aminobutyric acid, Allosteric regulation, Allosteric modulator

SAN711 is a first-in-class positive allosteric modulator of GABA-A 3 that was designed using Sanionas ion channel drug discovery engine.

Key Points: 
  • SAN711 is a first-in-class positive allosteric modulator of GABA-A 3 that was designed using Sanionas ion channel drug discovery engine.
  • While existing molecules target all GABA-A receptors indiscriminately, SAN711 selectively enhances the effects of GABA-A on 3 containing receptors.
  • Saniona also plans to continue to share its data on SAN711 and other preclinical programs in additional scientific and investor forums.
  • Saniona expects to begin a Phase 1 study of SAN711 in healthy volunteers in mid-2021, with data expected in early 2022.

Ketamine One Signs Definitive Agreement to Acquire Integrated Rehab and Performance Ltd.

Retrieved on: 
Thursday, June 3, 2021
Psychoactive drugs, Drugs, Neurochemistry, NMDA receptor antagonists, Antidepressants, Arylcyclohexylamines, Nicotinic antagonists, General anesthetics, Ketamine, Clinic

Pursuant to the terms of the Agreement and subject to the closing of the Transaction, IRPs Founder and Chief Executive Officer (CEO), Steven Inglefield, has agreed to become a director of Ketamine One.

Key Points: 
  • Pursuant to the terms of the Agreement and subject to the closing of the Transaction, IRPs Founder and Chief Executive Officer (CEO), Steven Inglefield, has agreed to become a director of Ketamine One.
  • The IRP team is excited to join Ketamine One and combine resources to grow its clinics across Canada.
  • Currently, Ketamine One has a network of 15 clinics across North America, with plans to further consolidate the highly fragmented industry.
  • As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.

Ketamine (CAS 6740-88-1) Global Market Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 3, 2021
Health, General Health, Psychoactive drugs, Drugs, Neurochemistry, Arylcyclohexylamines, Ketones, Dissociative drugs, NMDA receptor antagonists, Nicotinic antagonists, Ketamine

The "Ketamine (CAS 6740-88-1) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Ketamine (CAS 6740-88-1) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Ketamine.
  • The fifth chapter deals with Ketamine market trends and forecast, distinguish Ketamine manufacturers and suppliers.
  • The Ketamine global market report key points:

Artelo Biosciences to Present at the LD Micro Virtual Invitational XI on June 9th

Retrieved on: 
Wednesday, June 2, 2021
Cannabinoids, Neurochemistry, Endocannabinoid system

LA JOLLA, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL ), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced that management will present at the LD Micro Invitational XI investor conference taking place virtually June 8-10, 2021.

Key Points: 
  • LA JOLLA, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL ), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced that management will present at the LD Micro Invitational XI investor conference taking place virtually June 8-10, 2021.
  • Gregory D. Gorgas, Artelos President and CEO, is scheduled to host a virtual presentation to investors during the event as follows:
    For more information on the LD Micro Invitational XI, or to register for the event, please visit https://ldmicrojune2021.mysequire.com .
  • Artelo Biosciences, Inc.is a San Diego-based biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting endogenous signaling pathways including the endocannabinoid system.
  • Artelo is rapidly advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, PTSD, pain, and inflammation.

Myconic Capital Becomes Ketamine One

Retrieved on: 
Tuesday, June 1, 2021
Psychoactive drugs, Drugs, Neurochemistry, General anesthetics, Arylcyclohexylamines, Dissociative drugs, Nicotinic antagonists, Sedatives, Ketamine

VANCOUVER, British Columbia, June 01, 2021 (GLOBE NEWSWIRE) -- Myconic Capital Corp. (NEO: MEDI) is pleased to announce that effective June 3, 2021 it will change its name to KetamineOne Capital Limited (Ketamine One or the Company) from Myconic Capital Corp. and do business under the Ketamine One brand (the Name Change).

Key Points: 
  • VANCOUVER, British Columbia, June 01, 2021 (GLOBE NEWSWIRE) -- Myconic Capital Corp. (NEO: MEDI) is pleased to announce that effective June 3, 2021 it will change its name to KetamineOne Capital Limited (Ketamine One or the Company) from Myconic Capital Corp. and do business under the Ketamine One brand (the Name Change).
  • Ketamine Ones board of directors has appointed Dr. Mark Kimmins as the Companys Chief Medical Officer.
  • We are excited to reveal the re-brand of the Company to Ketamine One, which more accurately reflects our vision to quickly become a leader in the delivery of breakthrough mental wellbeing treatments, said Adam Deffett, VP of Capital Markets for Ketamine One.
  • KetamineOne Capital Limited (formerly Myconic Capital Corp.) (NEO: MEDI) is a single-purpose company focused becoming a North American leader in mental health.

Best-selling author of Your Brain on Porn, Gary Wilson, has passed away

Retrieved on: 
Wednesday, May 26, 2021
DC Comics characters, Arion, Gary Wilson, Neurochemistry, DC Comics

Gary Wilson is survived by his wife, Marnia Robinson, his son, Arion Sprague, and his canine companion, Smokey.

Key Points: 
  • Gary Wilson is survived by his wife, Marnia Robinson, his son, Arion Sprague, and his canine companion, Smokey.
  • In his personal life, Wilson was a wonderful husband, father, and friend, and he was loved by many.
  • Gary Wilson taught human pathology, anatomy, and physiology for years and has long been interested in the neurochemistry of addiction, mating, and bonding.
  • Gary Wilson cannot be replicated or replaced, but his legacy will live on through the enormous impact that he had.

Zynerba Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

Retrieved on: 
Wednesday, May 26, 2021
Drugs, Antiemetics, Entheogens, Tetrahydrocannabinol, Cannabinoid, Neurochemistry, Psychoactive drugs

DEVON, Pa., May 26, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will present a company overview during the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 4:30 p.m.

Key Points: 
  • DEVON, Pa., May 26, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will present a company overview during the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 4:30 p.m.
  • Investors interested in arranging a virtual meeting with the Companys management during the conference should contact the Jefferies conference coordinator.
  • A webcast of the presentation will be available under the Events & Webcasts tab of the Investors section of the Zynerba website at www.zynerba.com .
  • Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders.

Hemp Seed Breeders Need Academic Research to Solve Total THC Problem

Retrieved on: 
Tuesday, May 25, 2021
Herbs, Biofuels, Hemp, Entheogens, Euphoriants, Drugs, Tetrahydrocannabinol, Psychoactive drugs, Neurochemistry

LONGMONT, Colo., May 25, 2021 /PRNewswire/ -- Hemp seed breeders must collaborate with academic-run, varietal trials to tackle hemp's total THC problem and move the industry forward, says Matt Haddad, CEO of Trilogene Seeds , an award-winning hemp seed breeder.

Key Points: 
  • LONGMONT, Colo., May 25, 2021 /PRNewswire/ -- Hemp seed breeders must collaborate with academic-run, varietal trials to tackle hemp's total THC problem and move the industry forward, says Matt Haddad, CEO of Trilogene Seeds , an award-winning hemp seed breeder.
  • "We need to bring more academic analysis to these hemp varietals, especially with the .3 total THC iron fist coming down."
  • This spring, Haddad donated seeds from 12 Trilogene-bred hemp cultivars for the Midwestern Hemp Database (MHD), a collaboration between multiple universities, hemp seed breeders and growers.
  • However, harvesting a profitable CBD hemp crop without going over the .3% THC limit has been challenging for many growers.

Avadel Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

Retrieved on: 
Tuesday, May 25, 2021
Psychoactive drugs, Sleep disorders, Branches of biology, Neurochemistry, Narcolepsy, Sodium oxybate, Cataplexy, gamma-Hydroxybutyric acid, Excessive daytime sleepiness, Food and Drug Administration, Pitolisant, Idiopathic hypersomnia

ET.

Key Points: 
  • ET.
  • A live webcast of this event, as well as an archived recording, will be available on Avadels Investor Relations website, www.investors.avadel.com , for 90 days following the conference.
  • Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company primarily focused on the development and FDA approval of FT218, an investigational, once-nightly, extended-release formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy.
  • For more information, please visit www.avadel.com .

/R E P E A T -- Braxia Scientific Announces Symbol Change on OTC markets to "BRAXF"/

Retrieved on: 
Friday, May 21, 2021
Psychoactive drugs, Drugs, Neurochemistry, Communication, Forward-looking statement, Entheogens, Ketamine, Psilocybin

Braxia Scientific is primarily focused on (i) owning and operating multidisciplinary clinics providing treatment for mental health disorders and (ii) research activities related to discovering and commercializing novel drugs and delivery methods.

Key Points: 
  • Braxia Scientific is primarily focused on (i) owning and operating multidisciplinary clinics providing treatment for mental health disorders and (ii) research activities related to discovering and commercializing novel drugs and delivery methods.
  • The Company develops ketamine and psilocybin derivatives and other psychedelic products from its IP development platform.
  • All statements that are not historical facts, future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations, or beliefs of future performance are "forward-looking statements."
  • These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements.